Patents matching “formulation”

US 8337815

Pulmonary surfactant formulations

Discovery Laboratories, Inc. · Granted Dec 25, 2012 · Expires Dec 20, 2032

US 8323634

Stable formulations of highly concentrated recombinant human albumin-human granulocyte colony stimulating factor

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 4, 2012 · Expires Nov 29, 2032

US 8303995

Nitrite formulations and their use as nitric oxide prodrugs

The Board of Regents of the University of Texas System · Granted Nov 6, 2012 · Expires Nov 1, 2032

US 8298589

Nitrite formulations and their use as nitric oxide prodrugs

The Board of Regents of the University of Texas System · Granted Oct 30, 2012 · Expires Oct 25, 2032

US 8298580

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. · Granted Oct 30, 2012 · Expires Oct 25, 2032

US 8298576

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. · Granted Oct 30, 2012 · Expires Oct 25, 2032

US 8246984

Formulation of insoluble small molecule therapeutics in lipid-based carriers

Rigel Pharmaceuticals, Inc. · Granted Aug 21, 2012 · Expires Aug 16, 2032

US 8236780

Galactose—pronged polysaccharides in a formulation for antifibrotic therapies

GALECTIN THERAPEUTICS, INC. · Granted Aug 7, 2012 · Expires Aug 2, 2032

US 8221772

Pulmonary surfactant formulations and methods for promoting mucus clearance

Discovery Laboratories, Inc. · Granted Jul 17, 2012 · Expires Jul 12, 2032

US 8206740

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Jun 26, 2012 · Expires Jun 21, 2032

US 8188067

Formulations of 6-mercaptopurine

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 29, 2012 · Expires May 24, 2032

US 8158601

Lipid formulation

Alnylam Pharmaceuticals, Inc. · Granted Apr 17, 2012 · Expires Apr 12, 2032

US 8110546

VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Feb 7, 2012 · Expires Feb 2, 2032

US 8092803

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2012 · Expires Jan 5, 2032

US 8084058

Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Takeda Pharmaceutical Company Limited · Granted Dec 27, 2011 · Expires Dec 22, 2031

US 8080584

Delayed release rasagiline citrate formulation

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 20, 2011 · Expires Dec 15, 2031

US 8058226

Albumin-free factor VIII formulations

UNIVERSITY OF CONNECTICUT · Granted Nov 15, 2011 · Expires Nov 10, 2031

US 8034376

Lipid containing formulations

Alnylam Pharmaceuticals, Inc. · Granted Oct 11, 2011 · Expires Oct 6, 2031

US 8003126

Stable tablet formulation

BIOMARIN PHARMACEUTICAL INC. · Granted Aug 23, 2011 · Expires Aug 18, 2031

US 7964561

Protein formulations for use at elevated temperatures

Advanced Technologies and Regenerative Medicine, LLC · Granted Jun 21, 2011 · Expires Jun 16, 2031

US 7956086

Methods for the formulation and manufacture of artesunic acid for injection

The United States of America as represented by the Secretary of the Army · Granted Jun 7, 2011 · Expires Jun 2, 2031

US 7956028

Protein stabilization formulations

JOHNSON & JOHNSON REGENERATIVE THERAPEUTICS, LLC · Granted Jun 7, 2011 · Expires Jun 2, 2031

US 7947649

Liquid buffered GDF-5 formulations

Advanced Technologies and Regenerative Medicine, LLC · Granted May 24, 2011 · Expires May 19, 2031

US 7910131

Method of treating seizures using modified release formulations of oxcarbazepine

Supernus Pharmaceuticals, Inc. · Granted Mar 22, 2011 · Expires Mar 17, 2031